Publications

by | April 1, 2010 | Uncategorized

The Generic Drugs Forum calls for attention to the lack of training and information around generic medicines.

The Generic Drugs Forum held its first meeting on March 2nd in Madrid. Participants were able to discuss current situation of generic drugs in Spain. Topics discussed included patient confidence, health professional perscriptions of generic drugs and modify the Reference Pricing System. The Generic Drugs Forum also made recommendations on how to improve the use of generic drugs.

On March 2nd in Madrid, the first meeting of the newly created Generic Drugs Forum took place. Participants shared ideas to improve the ailing situation of generic drugs in Spain. It was attended by more than 25 stakeholders involved in the pharmaceutical debate, including the European Public Health Alliance, which was represented by Wim Vandevelde (member of the EPHA Executive Committee). The Generic Forum is an initiative promoted by Fundamed (Fundacion de Ciencias del Medicamento y Productos Sanitarios), which gathers politicians, doctors, pharmacists, distributors and patients in order to analyse the reality of generic drugs in Spain and aims to propose measures for strengthening this market.

Among the issues raised by the participants were: the necessity to develop information campaigns for physicians and patients, the need to apply major changes to the reference pricing system, and the urge to accelerate the registration process by the Spanish Agency of Medicines (AEMPS).

Throughout the discussion, representatives from various medical institutions and from patient organisations, such as the General Patients’ Alliance, highlighted the lack of information surrounding generic drugs. Many people expressed confusion around the validity and effectiveness of these medicines. Specifically, users perceive that generic drugs do not often display the same quality as the brand name ones do, especially if their use implies frequent brand changes throughout the same treatment. For instance, Patient Organizations dealing with chronic diseases mention that continuous change in the treatment often creates uncertainty about the outcome of therapy. For this reason, in many cases, patients are reluctant to leave the brand they are used to.

Meanwhile, doubts are also raised by medical professionals because, although doing everything possible to prescribe generic medicines, they often have to deal with patients who are reluctant to consumption. Moreover, they say it is difficult to deal with the great number of drugs that are launched into the market every year.

In order to tackle these problems, the Generic Drugs Forum highlights the need for education, information and awareness campaigns for both physicians and patients, with the objective of spreading a clear message about the quality of generic drugs and thus avoiding the distrust of citizens, who often associates generic drugs with cheap solutions. These campaigns should be organised and supported by the different Autonomous Communities in collaboration with the Spanish Agency of Medicines (AEMPS).

Modify the Reference Pricing System

One issue that everybody agreed with is the need to modify the Reference Pricing System (RPS). According to the Generic Forum members, this system, which is designed solely to achieve lower prices, has hurt, paradoxically, the development of generics. In the view of some members of the Generic Forum, the system is showing signs of exhaustion: after 12 years with the Reference Pricing System, technical errors seem to get worse every year instead of improving.

The officials added that the calculation of prices on a daily defined doses (DDD) basis is not consistent with the dose effectively in use in Spain and does not take into account the various directions of the same active ingredient and its different dosage forms, with specific production characteristics. Establishing a minimum market share for drugs used in the calculation of reference prices is one request submitted, as it is frequent the use of products that are neither marketed nor available in the entire market. A system based on market shares for the calculation of minimum reference price, as well as for establishing the lower price, would reduce the impact caused by some laboratories that have no intention to launch products into the market.

Another change that is considered necessary is revising the reference price threshold of 2 euros, which may impede the manufacturing of products with minimum standards. Moreover, the Ministry of Health should regulate the entering into the market of lower prices throughout the country, eliminating the need for brands to stick to the reference price. If brands are forced to reduce their price, there is no competition with generic drugs, and thus no possibilities to develop different marketing strategies.

Criticism of AEMPS

Another issue that was raised by the participant was the delay in the authorisation process by the Medicines Agency (AEMPS). In some case it may take more than 24 months to have the opinion of the Agency, compared to seven months as a general rule usually takes to approve.

In this sense, AEMPS was requested to allocate more resources to the evaluation of generic drugs, since they are the main source of income, in the form of taxes, to the Agency

First recommendations.

Furthermore, the Generic Drugs Forum proposed the possibility of reduce the co-payment contribution in case of a generic drug, with the aim of increasing demand from patients and reach market shares similarly to the European average. Another proposal, which came to light during the day, is that anyone who wants to register a drug should provide a guarantee or commitment to supply a minimum amount. This would ensure an end to the so-called ‘labs kamikaze’, whose sole purpose is to drive down costs.

On the other hand, doctor proposed the elimination of “coercive measures” that are being applied to physicians to encourage prescription of generics and that are not helping their trust in such medicines. In this sense, the Generic Forum also highlighted that in countries where the use of generic drugs is higher and is more settled, the prescription of these is voluntary.

Get the EPHA Newsletter

The best of our activities, right in your inbox!